NUTXHealthcare · Medical Care FacilitiesThe 6 Wall Street analysts covering Nutex Health, Inc. hold a median 12-month price target of $308 — +50.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Nutex Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Volatility (13): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NUTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +50.1% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Oct 2026 | Ladenburg Thalmann | Initiates | Buy | $336 |
| 25 Sept 2026 | Freedom Capital Markets | Maintains | Buy | $280 → $306 |
| 25 Sept 2026 | Freedom Capital Markets | Maintains | Buy | — |
| 4 Sept 2026 | B. Riley Securities | Maintains | Buy | $290 → $325 |
| 4 Sept 2026 | B. Riley Securities | Maintains | Buy | — |
| 11 Aug 2026 | Lake Street | Maintains | Buy | $235 → $310 |
| 11 Aug 2026 | Lake Street | Maintains | Buy | — |
| 26 June 2026 | B. Riley Securities | Initiates | Buy | $290 |
| 26 June 2026 | B. Riley Securities | Initiates | Buy | — |
| 2 June 2026 | Lake Street | Initiates | Buy | — |
| 26 Aug 2025 | Maxim Group | Maintains | Buy | — |
| 10 July 2025 | Benchmark | Reiterates | Buy | — |
| 20 May 2025 | Maxim Group | Maintains | Buy | — |
| 15 May 2025 | Benchmark | Maintains | Buy | — |
| 9 Apr 2025 | Benchmark | Maintains | Buy | — |
| 8 Apr 2025 | Maxim Group | Maintains | Buy | — |
| 13 Feb 2025 | Maxim Group | Maintains | Buy | — |
| 12 Nov 2024 | Benchmark | Maintains | Buy | — |
| 12 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 18 Sept 2024 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NUTX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Nutex Health, Inc. returned +62.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 62% of US stocks
Cheaper than 57% of US stocks
Cheaper than 27% of US stocks
Cheaper than 56% of US stocks
Higher than 14% of US stocks
Higher than 24% of US stocks
Higher than 80% of US stocks
Higher than 98% of US stocks
Higher than 83% of US stocks
Higher than 94% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nutex Health, Inc. has a market value of $1.2B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $846.7M. The latest quarter shrank 13.6% year on year.
Net income over the same four quarters: $272.5M, a 32.2% net margin.
Free cash flow in the twelve months to 30 June 2026: $274.2M.
Nutex Health, Inc. spent $84.1M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 7.9×; forward P/E: 9.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nutex Health, Inc. employs 1,037 people — $817K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nutex Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nutex Health faces Q3 revenue pressure from reimbursement uncertainty, while rising patient volumes and lower arbitration costs may support profitability.
Why it matters — NUTX watchers may weigh potential cost savings and volume growth against uncertainty around reimbursement-related revenue.
The article says the AI-driven rally may continue amid stronger-than-expected Q3 U.S. GDP growth and robust consumer spending, while citing a softer job market, sticky inflation and tight financial conditions. It also notes JPMorgan Asset Management’s finding that stocks have historically risen nearly 15% on average after midterm elections.
Why it matters — The excerpt discusses broad market conditions and historical post-midterm performance but gives no NUTX-specific information.
Nutex Health plans to file its Form 10-Q for the third quarter ended Sept. 30, 2026, after market close on Nov. 5, 2026.
Why it matters — The filing date gives NUTX watchers a timeframe for the company’s third-quarter financial results.
A Seeking Alpha article says healthcare may offer both growth potential and defensive characteristics amid macroeconomic uncertainty, citing aging demographics, rising medical demand, and spending growth. It highlights select healthcare services and facilities companies with strong forward revenue, EBITDA, and earnings growth.
Why it matters — The article discusses broad trends relevant to healthcare services and facilities, but the excerpt does not specifically address Nutex Health.
Zacks Investment Research highlighted Nutex Health (NUTX) among five stocks showing recent price strength and strong momentum after a mixed September, with improving earnings estimates noted.
Why it matters — A NUTX watcher would care because the stock is being called out for recent price strength and improving earnings estimates, signaling positive momentum for the company.
The 6 Wall Street analysts covering Nutex Health, Inc. have a median 12-month price target of $308, with estimates ranging from $200 to $336. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Nutex Health, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nutex Health, Inc. 75 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Nutex Health, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +50.1% from the last close, and Ticker Nerd's factor model ranks Nutex Health, Inc. 75 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nutex Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $336 over the next 12 months.
Nutex Health, Inc. returned +62.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Nutex Health Inc. is a healthcare management and operations company that provides care delivery and support services through its Hospital Division and Population Health Management Division.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Nutex Health Q3 Earnings: Can Cost Savings Offset Revenue Risks?". Nutex Health faces Q3 revenue pressure from reimbursement uncertainty, while rising patient volumes and lower arbitration costs may support profitability.
Nutex Health Inc. is a healthcare management and operations company that provides care delivery and support services through its Hospital Division and Population Health Management Division. Nutex Health operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer emergency care, inpatient services, behavioral health, imaging, laboratory testing, and pharmacy services. Its population health business builds and manages provider networks, including independent physician associations, and provides administrative and technology support through a cloud-based platform. The company also includes a real estate segment that owns and leases hospital properties. Nutex Health serves patients and physician groups across multiple U.S. states, with a model centered on integrated local healthcare access and coordinated care operations.
CEO Dr. Thomas T. Vo M.B.A., M.D. · 1,037 employees · United States · https://www.nutexhealth.com
